盾叶冠心宁治疗冠心病合并高同型半胱氨酸血症患者临床观察
|
摘要
目的探讨盾叶冠心宁片对冠心病合并高同型半胱氨酸(Hcy)血症患者Hcy及血脂的影响。方法选取冠心病合并高Hcy血症患者120例,采用随机数字表法分为观察组与对照组,各60例,观察组给予基础治疗+盾叶冠心宁片;对照组给予基础治疗+叶酸及甲钴胺片。治疗30 d后观察患者血清Hcy、总胆固醇(TC)、低密度脂蛋白-C(LDL-C)、高密度脂蛋白-C(HDL-C)及三酰甘油(TG)变化。结果治疗后,2组Hcy较前均有下降,差异无统计学意义(P>0.05);观察组TC(3.72±0.53)mmol/L、LDL-C(1.67±0.29)mmol/L及TG(1.04±0.48)mmol/L,较对照组的(3.91±0.45)mmol/L、(1.82±0.27)mmol/L及(1.21±0.41)mmol/L水平下降更明显,差异有统计学意义(P<0.05);观察组HDL-C(1.04±0.25)mmol/L,较对照组的(1.04±0.22)mmol/L略有升高,差异无统计学意义(P>0.05)。结论盾叶冠心宁片可降低Hcy水平,调节血脂。
Objective To investigate the effect of the prescription of DunyeGuanxinning tablet on homocysteine and blood lipid in patients with coronary heart disease complicated with Hyperhomocysteinemia. Methods 120 patients with coronary heart disease complicated with Hyperhomocysteinemia were selected. and were randomly divided into observation group(60 cases given basic treatment+Dunye Guanxinning tablet) and control group(60 cases, given basic treatment+folic acid and methylcobalamin). After treatment for 30 days, serum homocysteine(Hcy), total cholesterol(TC), low-density lipoprotein-C(LDL-C),high-density lipoprotein-C(HDL-C)and triglyceride(TG) were observed. Results After treatment, homocysteine the two groups decreased than before. There was no significant difference between the two groups(P>0.05). The total cholesterol in the observation group decreased(3.72±0.53)mmol/L, low density lipoprotein-C(1.67±0.29)mmol/L and triglyceride levels(1.04±0.48)mmol/L decreased more than the control group. There was significant difference between the two groups(P<0.05). two groups of High density lipoprotein-C observation group(1.04±0.25)mmol/L, control group(1.04±0.22)mmol/L were slightly higher. The difference was not statistically significant(P>0.05). Conclusion DunyeGuanxinning tablet can lower Hyperhomocysteinemia levels, and has certain clinical effect on regulating blood lipid.
Objective To investigate the effect of the prescription of DunyeGuanxinning tablet on homocysteine and blood lipid in patients with coronary heart disease complicated with Hyperhomocysteinemia. Methods 120 patients with coronary heart disease complicated with Hyperhomocysteinemia were selected. and were randomly divided into observation group(60 cases given basic treatment+Dunye Guanxinning tablet) and control group(60 cases, given basic treatment+folic acid and methylcobalamin). After treatment for 30 days, serum homocysteine(Hcy), total cholesterol(TC), low-density lipoprotein-C(LDL-C),high-density lipoprotein-C(HDL-C)and triglyceride(TG) were observed. Results After treatment, homocysteine the two groups decreased than before. There was no significant difference between the two groups(P>0.05). The total cholesterol in the observation group decreased(3.72±0.53)mmol/L, low density lipoprotein-C(1.67±0.29)mmol/L and triglyceride levels(1.04±0.48)mmol/L decreased more than the control group. There was significant difference between the two groups(P<0.05). two groups of High density lipoprotein-C observation group(1.04±0.25)mmol/L, control group(1.04±0.22)mmol/L were slightly higher. The difference was not statistically significant(P>0.05). Conclusion DunyeGuanxinning tablet can lower Hyperhomocysteinemia levels, and has certain clinical effect on regulating blood lipid.
引文
[1] 雷震山,杜剑强,尹云华.检测同型半胱氨酸对冠心病的早期诊断价值分析[J].现代诊断与治疗,2018,29(12):1856-1858.
[2] SHAH H,JAN M U,ALTAF A,et al.Correlation of hyper-homocysteinemia with coronary artery disease in absence of conventional risk factors among young adults[J].J Saudi Heart Assoc,2018,30(4):305-310.
[3] 韦艳红.盾叶冠心宁治疗冠心病心绞痛临床疗效观察[J].中西医结合心血管病电子杂志,2018,6(12):38.
[4] 徐济民.缺血性心脏病诊断的命名及标准——国际心脏病学会和协会/世界卫生组织临床命名标准化专题组的联合报告[J].国外医学(心血管疾病分册),1979(6):365-366.
[5] GUO H Y,XU F K,LV H T,et al.Hyperhomocysteinemia independently causes and promotes atherosclerosis in LDL receptor-deficient mice[J].J Geriatr Cardiol,2014,11(1):74-78.
[6] 王生.高同型半胱氨酸与冠心病的相关分析[J].当代医学,2016,22(32):54-55.
[7] 张琛涛,莫新玲.冠心病、高血压与血清同型半胱氨酸、超敏 C 反应蛋白的相关性[J].中国老年学杂志,2013,33(5):1035-1037.
[8] 鄢高亮,王栋,乔勇,等.高同型半胱氨酸水平对冠心病严重程度及支架置入治疗预后的影响[J].中华心血管病杂志,2015,3(11):943-947.
[9] 付伟光,齐振勇,李爱军,等 .HCY、Hs-CRP、LP(a) 及 DD 联合检测在冠心病病程中的应用研究[J].现代预防医学,2014,41(1):124-127.
[10] 韩钰,杨帆,丛恬駪,等.薯蓣皂苷对大鼠心肌收缩力影响的研究[J].中国药理学通报,2016,32(2):258-262.
[11] 方珂.胡芦巴丸活性组分改善糖脂代谢紊乱的机理研究[D].武汉:华中科技大学,2017.
[12] 王宏伟.薯蓣皂苷元对大鼠心肌缺血再灌注损伤的抗炎作用[D].南京:南京医科大学,2018.
[13] 孙伟青,刘刚,郑明奇.盾叶冠心宁治疗冠心病的临床疗效及对患者血清同性半胱氨酸的影响[J].临床合理用药,2016,9(4):26-27.
[2] SHAH H,JAN M U,ALTAF A,et al.Correlation of hyper-homocysteinemia with coronary artery disease in absence of conventional risk factors among young adults[J].J Saudi Heart Assoc,2018,30(4):305-310.
[3] 韦艳红.盾叶冠心宁治疗冠心病心绞痛临床疗效观察[J].中西医结合心血管病电子杂志,2018,6(12):38.
[4] 徐济民.缺血性心脏病诊断的命名及标准——国际心脏病学会和协会/世界卫生组织临床命名标准化专题组的联合报告[J].国外医学(心血管疾病分册),1979(6):365-366.
[5] GUO H Y,XU F K,LV H T,et al.Hyperhomocysteinemia independently causes and promotes atherosclerosis in LDL receptor-deficient mice[J].J Geriatr Cardiol,2014,11(1):74-78.
[6] 王生.高同型半胱氨酸与冠心病的相关分析[J].当代医学,2016,22(32):54-55.
[7] 张琛涛,莫新玲.冠心病、高血压与血清同型半胱氨酸、超敏 C 反应蛋白的相关性[J].中国老年学杂志,2013,33(5):1035-1037.
[8] 鄢高亮,王栋,乔勇,等.高同型半胱氨酸水平对冠心病严重程度及支架置入治疗预后的影响[J].中华心血管病杂志,2015,3(11):943-947.
[9] 付伟光,齐振勇,李爱军,等 .HCY、Hs-CRP、LP(a) 及 DD 联合检测在冠心病病程中的应用研究[J].现代预防医学,2014,41(1):124-127.
[10] 韩钰,杨帆,丛恬駪,等.薯蓣皂苷对大鼠心肌收缩力影响的研究[J].中国药理学通报,2016,32(2):258-262.
[11] 方珂.胡芦巴丸活性组分改善糖脂代谢紊乱的机理研究[D].武汉:华中科技大学,2017.
[12] 王宏伟.薯蓣皂苷元对大鼠心肌缺血再灌注损伤的抗炎作用[D].南京:南京医科大学,2018.
[13] 孙伟青,刘刚,郑明奇.盾叶冠心宁治疗冠心病的临床疗效及对患者血清同性半胱氨酸的影响[J].临床合理用药,2016,9(4):26-27.